Business Context and Reporting Period
Climb Bio, Inc. (CLYM), a Delaware corporation and emerging growth company, filed this Form 8-K on April 27, 2026. The filing reports the entry into a Material Definitive Agreement for a private placement of equity securities. The company is focused on the development of product candidates including budoprutug and CLYM116 for immune-mediated diseases.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of common stock and pre-funded warrants.
- Expected Gross Proceeds: Approximately $110.0 million (before fees and expenses).
- Securities Issued:
- 9,481,000 shares of common stock at $9.50 per share.
- 2,106,000 pre-funded warrants at $9.4999 per warrant.
- Expected Closing Date: On or about April 29, 2026.
- Placement Agents: Leerink Partners LLC and Piper Sandler and Co. (lead agents); Raymond James, BTIG, Robert W. Baird, and H.C. Wainwright (co-agents).
- Investors: Institutional accredited investors, including an affiliate of RA Capital Management.
Material Changes and Agreements
The filing details the execution of a Securities Purchase Agreement and a Registration Rights Agreement. Key terms include:
- Pre-Funded Warrants: Exercisable immediately at $0.0001 per share. Beneficial ownership limitations apply (generally 4.99% or 9.99%, with RA Capital capped at 33.0% unless increased with notice).
- Registration Rights: The Company must file a registration statement for resale of securities within 45 days of closing and keep it effective until all securities are resold or Rule 144 exemptions apply.
- Exchange Agreement: Shares issued to RA Capital are subject to a prior Exchange Agreement requiring RA Capital to vote excess securities in proportion to other stockholders.
Outlook, Risks, and Management Commentary
Cash Runway: Management estimates that current cash resources combined with the anticipated net proceeds from the private placement will facilitate continued execution towards late-stage development.
Risks and Uncertainties: The filing includes standard forward-looking statement disclaimers. Specific risks cited include:
- Ability to achieve benefits from the technology transfer agreement with Beijing Mabworks Biotech Co., Ltd.
- Regulatory approval timelines for budoprutug and CLYM116 from the FDA and other authorities.
- Replicating early-stage clinical results in later trials.
- Competition in treating primary membranous nephropathy, immune thrombocytopenia, and other immune-mediated diseases.
- Need to raise substantial additional capital in the future.
Investor Verification Checklist
- Verify the actual closing date and final net proceeds after deducting placement agent fees and offering expenses.
- Confirm the filing of the resale registration statement within the 45-day deadline post-closing.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and indemnification terms.
- Monitor the status of the technology transfer agreement with Beijing Mabworks Biotech Co., Ltd.
- Assess the dilution impact of the 9,481,000 shares and 2,106,000 pre-funded warrants on existing shareholders.